Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.

PloS one - 1 Jan 2024

Yong Chee Meng, Yehgambaram Prathepamalar A P, Lee Shaun Wen Huey

Abstract excerpt

INTRODUCTION: Ovarian cancer is one of the most common cancer among women in Malaysia. Patients with ovarian cancer are often diagnosed at an advanced stage. Despite initial response to surgery and chemotherapy, most patients will experience a relapse. Olaparib has been reported have promising effects among BRCA mutated ovarian cancer patients. This study aimed to evaluate the cost-effectiveness of olaparib as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Malaysia
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Quality-Adjusted Life Years

Source

Open in PubMed Open full text

Identifiers

PMID: 38300930
DOI: 10.1371/journal.pone.0298130
PMCID: PMC10833573

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.PMID 38300930Read ↗

Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer.Semantic proximity Read ↗

Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.Semantic proximity Read ↗

Cost-effectiveness of PARP inhibitors for maintenance therapy of patients with a BRCA mutation and primary epithelial ovarian cancer in ChinaSemantic proximity Read ↗

Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.Semantic proximity Read ↗

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.Semantic proximity Read ↗

Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.Semantic proximity Read ↗

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.Semantic proximity Read ↗

Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancerSemantic proximity Read ↗

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian CancerSemantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

A discrete event simulation to evaluate the cost effectiveness of germline <i>BRCA1</i> and <i>BRCA2</i> testing in UK women with ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.